NCT07421050

Clinical Trial of Subunit Influenza Vaccine (Adjuvant) in Chinese Population Aged 65 Years and Older

A Randomized, Blinded, Controlled Phase I Clinical Trial to Evaluate the Safety of a Subunit Influenza Vaccine (Adjuvant) in Adults Aged 65 Years and Older

• Status: Active Not Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 80 (actual)
• Sponsor: Ab&B Bio-tech Co., Ltd.JS · Academic / Other
• Sex: All
• Age: 65 Years
• Healthy volunteers: Accepted

Summary

The objective of this study was to evaluate the safety of subunit influenza vaccine (adjuvant) in people aged 65 years and older.

Conditions

• Influenza
• Influenza Vaccine

Interventions

Type	Name	Description
BIOLOGICAL	Subunit Influenza Vaccine (Adjuvant)	A single 0.25 mL dose is administered intramuscularly into the deltoid muscle of the upper arm on Day 0.
BIOLOGICAL	Subunit Influenza Vaccine (Adjuvant)	A single 0.5 mL dose is administered intramuscularly into the deltoid muscle of the upper arm on Day 0.
BIOLOGICAL	MF59	A single 0.5 mL dose is administered intramuscularly into the deltoid muscle of the upper arm on Day 0
BIOLOGICAL	0.9% sodium chloride injection (normal saline)	A single 0.5 mL dose is administered intramuscularly into the deltoid muscle of the upper arm on Day 0.

Timeline

• Start date: 2025-11-13
• Primary completion: 2026-12-13
• Completion: 2026-12-13
• First posted: 2026-02-19
• Last updated: 2026-02-19

Locations

1 site across 1 country: China